Head-To-Head Review: IDEXX Laboratories (NASDAQ:IDXX) & CardioGenics (OTCMKTS:CGNH)

IDEXX Laboratories (NASDAQ:IDXX) and CardioGenics (OTCMKTS:CGNH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Institutional and Insider Ownership

87.8% of IDEXX Laboratories shares are held by institutional investors. 1.0% of IDEXX Laboratories shares are held by company insiders. Comparatively, 41.4% of CardioGenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for IDEXX Laboratories and CardioGenics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0	4	7	1	2.75
CardioGenics	0	0	0	0	0.00

IDEXX Laboratories presently has a consensus target price of $730.50, suggesting a potential downside of 2.99%. Given CardioGenics’ higher possible upside, analysts clearly believe CardioGenics is more favorable than IDEXX Laboratories.

Volatility & Risk

IDEXX Laboratories has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, CardioGenics has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500.

Earnings and Valuation

This table compares IDEXX Laboratories and CardioGenics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.17 billion	14.43	$887.87 million	$12.61	59.72
CardioGenics	N/A	N/A	N/A	N/A	N/A

IDEXX Laboratories has higher revenue and earnings than CardioGenics.

Profitability

This table compares IDEXX Laboratories and CardioGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.41%	64.42%	29.89%
CardioGenics	N/A	N/A	N/A

Summary

IDEXX Laboratories beats CardioGenics on 8 of the 11 factors compared between the two stocks.

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.